Gilead's HIV Prevention Drug Could Be Manufactured At Shocking Low Cost: Report

Why is Amazon cutting corporate jobs due to AI? How did Middle East tensions impact oil prices? What caused the recent plunge in solar stocks? Why did At Home file for bankruptcy? How will Kraft Heinz’s dye removal affect products? Why is the Senate passing a stablecoin regulation bill? What’s behind JPMorgan’s Sapphire Reserve fee hike?

Gilead's HIV Prevention Drug Could Be Manufactured At Shocking Low Cost: Report

benzinga.com/markets/large-cap/25/06/45982235/gileads-hiv-prevention-drug-could-be-manufactured-at-shocking-low-cost-report

Gilead Sciences Inc (NASDAQ:GILD) is facing mounting pressure to price its long-acting HIV prevention drug, lenacapavir, affordably as it prepares for U.S. regulatory approval on June 19.
In December 2022, the FDA approved Lenacapavir in combination with other antiretrovirals to treat…

This story appeared on benzinga.com, 2025-06-17 18:18:01.